The molecular classification of multiple myeloma

Fenghuang Zhan, Yongsheng Huang, Simona Colla, James P. Stewart, Ichiro Hanamura, Sushil Gupta, Joshua Epstein, Shmuel Yaccoby, Jeffrey Sawyer, Bart Burington, Elias Anaissie, Klaus Hollmig, Mauricio Pineda-Roman, Guido Tricot, Frits Van Rhee, Ronald Walker, Maurizio Zangari, John Crowley, Bart Barlogie, John D. Shaughnessy

Research output: Contribution to journalArticle

675 Citations (Scopus)

Abstract

To better define the molecular basis of multiple myeloma (MM), we performed unsupervised hierarchic clustering of mRNA expression profiles in CD138-enriched plasma cells from 414 newly diagnosed patients who went on to receive high-dose therapy and tandem stem cell transplants. Seven disease subtypes were validated that were strongly influenced by known genetic lesions, such as c-MAF- and MAFB-, CCND1- and CCND3-, and MMSET-activating translocations and hyperdiploidy. Indicative of the deregulation of common pathways by gene orthologs, common gene signatures were observed in cases with c-MAF and MAFB activation and CCND1 and CCND3 activation, the latter consisting of 2 subgroups, one characterized by expression of the early B-cell markers CD20 and PAX5. A low incidence of focal bone disease distinguished one and increased expression of proliferation-associated genes of another novel subgroup. Comprising varying fractions of each of the other 6 subgroups, the proliferation subgroup dominated at relapse, suggesting that this signature is linked to disease progression. Proliferation and MMSET-spike groups were characterized by significant overexpression of genes mapping to chromosome 1q, and both exhibited a poor prognosis relative to the other groups. A subset of cases with a predominating myeloid gene expression signature, excluded from the profiling analyses, had more favorable baseline characteristics and superior prognosis to those lacking this signature.

Original languageEnglish (US)
Pages (from-to)2020-2028
Number of pages9
JournalBlood
Volume108
Issue number6
DOIs
StatePublished - Sep 15 2006

Fingerprint

Multiple Myeloma
Genes
Polyploidy
Chromosome Mapping
Bone Diseases
Chemical activation
Plasma Cells
Transcriptome
Transplants
Deregulation
Cluster Analysis
Disease Progression
B-Lymphocytes
Stem Cells
Chromosomes
Stem cells
Gene expression
Recurrence
Messenger RNA
Bone

ASJC Scopus subject areas

  • Hematology

Cite this

Zhan, F., Huang, Y., Colla, S., Stewart, J. P., Hanamura, I., Gupta, S., ... Shaughnessy, J. D. (2006). The molecular classification of multiple myeloma. Blood, 108(6), 2020-2028. https://doi.org/10.1182/blood-2005-11-013458

The molecular classification of multiple myeloma. / Zhan, Fenghuang; Huang, Yongsheng; Colla, Simona; Stewart, James P.; Hanamura, Ichiro; Gupta, Sushil; Epstein, Joshua; Yaccoby, Shmuel; Sawyer, Jeffrey; Burington, Bart; Anaissie, Elias; Hollmig, Klaus; Pineda-Roman, Mauricio; Tricot, Guido; Van Rhee, Frits; Walker, Ronald; Zangari, Maurizio; Crowley, John; Barlogie, Bart; Shaughnessy, John D.

In: Blood, Vol. 108, No. 6, 15.09.2006, p. 2020-2028.

Research output: Contribution to journalArticle

Zhan, F, Huang, Y, Colla, S, Stewart, JP, Hanamura, I, Gupta, S, Epstein, J, Yaccoby, S, Sawyer, J, Burington, B, Anaissie, E, Hollmig, K, Pineda-Roman, M, Tricot, G, Van Rhee, F, Walker, R, Zangari, M, Crowley, J, Barlogie, B & Shaughnessy, JD 2006, 'The molecular classification of multiple myeloma', Blood, vol. 108, no. 6, pp. 2020-2028. https://doi.org/10.1182/blood-2005-11-013458
Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al. The molecular classification of multiple myeloma. Blood. 2006 Sep 15;108(6):2020-2028. https://doi.org/10.1182/blood-2005-11-013458
Zhan, Fenghuang ; Huang, Yongsheng ; Colla, Simona ; Stewart, James P. ; Hanamura, Ichiro ; Gupta, Sushil ; Epstein, Joshua ; Yaccoby, Shmuel ; Sawyer, Jeffrey ; Burington, Bart ; Anaissie, Elias ; Hollmig, Klaus ; Pineda-Roman, Mauricio ; Tricot, Guido ; Van Rhee, Frits ; Walker, Ronald ; Zangari, Maurizio ; Crowley, John ; Barlogie, Bart ; Shaughnessy, John D. / The molecular classification of multiple myeloma. In: Blood. 2006 ; Vol. 108, No. 6. pp. 2020-2028.
@article{d1315ccb4d894eb5bdc6734fe63a60dd,
title = "The molecular classification of multiple myeloma",
abstract = "To better define the molecular basis of multiple myeloma (MM), we performed unsupervised hierarchic clustering of mRNA expression profiles in CD138-enriched plasma cells from 414 newly diagnosed patients who went on to receive high-dose therapy and tandem stem cell transplants. Seven disease subtypes were validated that were strongly influenced by known genetic lesions, such as c-MAF- and MAFB-, CCND1- and CCND3-, and MMSET-activating translocations and hyperdiploidy. Indicative of the deregulation of common pathways by gene orthologs, common gene signatures were observed in cases with c-MAF and MAFB activation and CCND1 and CCND3 activation, the latter consisting of 2 subgroups, one characterized by expression of the early B-cell markers CD20 and PAX5. A low incidence of focal bone disease distinguished one and increased expression of proliferation-associated genes of another novel subgroup. Comprising varying fractions of each of the other 6 subgroups, the proliferation subgroup dominated at relapse, suggesting that this signature is linked to disease progression. Proliferation and MMSET-spike groups were characterized by significant overexpression of genes mapping to chromosome 1q, and both exhibited a poor prognosis relative to the other groups. A subset of cases with a predominating myeloid gene expression signature, excluded from the profiling analyses, had more favorable baseline characteristics and superior prognosis to those lacking this signature.",
author = "Fenghuang Zhan and Yongsheng Huang and Simona Colla and Stewart, {James P.} and Ichiro Hanamura and Sushil Gupta and Joshua Epstein and Shmuel Yaccoby and Jeffrey Sawyer and Bart Burington and Elias Anaissie and Klaus Hollmig and Mauricio Pineda-Roman and Guido Tricot and {Van Rhee}, Frits and Ronald Walker and Maurizio Zangari and John Crowley and Bart Barlogie and Shaughnessy, {John D.}",
year = "2006",
month = "9",
day = "15",
doi = "10.1182/blood-2005-11-013458",
language = "English (US)",
volume = "108",
pages = "2020--2028",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - The molecular classification of multiple myeloma

AU - Zhan, Fenghuang

AU - Huang, Yongsheng

AU - Colla, Simona

AU - Stewart, James P.

AU - Hanamura, Ichiro

AU - Gupta, Sushil

AU - Epstein, Joshua

AU - Yaccoby, Shmuel

AU - Sawyer, Jeffrey

AU - Burington, Bart

AU - Anaissie, Elias

AU - Hollmig, Klaus

AU - Pineda-Roman, Mauricio

AU - Tricot, Guido

AU - Van Rhee, Frits

AU - Walker, Ronald

AU - Zangari, Maurizio

AU - Crowley, John

AU - Barlogie, Bart

AU - Shaughnessy, John D.

PY - 2006/9/15

Y1 - 2006/9/15

N2 - To better define the molecular basis of multiple myeloma (MM), we performed unsupervised hierarchic clustering of mRNA expression profiles in CD138-enriched plasma cells from 414 newly diagnosed patients who went on to receive high-dose therapy and tandem stem cell transplants. Seven disease subtypes were validated that were strongly influenced by known genetic lesions, such as c-MAF- and MAFB-, CCND1- and CCND3-, and MMSET-activating translocations and hyperdiploidy. Indicative of the deregulation of common pathways by gene orthologs, common gene signatures were observed in cases with c-MAF and MAFB activation and CCND1 and CCND3 activation, the latter consisting of 2 subgroups, one characterized by expression of the early B-cell markers CD20 and PAX5. A low incidence of focal bone disease distinguished one and increased expression of proliferation-associated genes of another novel subgroup. Comprising varying fractions of each of the other 6 subgroups, the proliferation subgroup dominated at relapse, suggesting that this signature is linked to disease progression. Proliferation and MMSET-spike groups were characterized by significant overexpression of genes mapping to chromosome 1q, and both exhibited a poor prognosis relative to the other groups. A subset of cases with a predominating myeloid gene expression signature, excluded from the profiling analyses, had more favorable baseline characteristics and superior prognosis to those lacking this signature.

AB - To better define the molecular basis of multiple myeloma (MM), we performed unsupervised hierarchic clustering of mRNA expression profiles in CD138-enriched plasma cells from 414 newly diagnosed patients who went on to receive high-dose therapy and tandem stem cell transplants. Seven disease subtypes were validated that were strongly influenced by known genetic lesions, such as c-MAF- and MAFB-, CCND1- and CCND3-, and MMSET-activating translocations and hyperdiploidy. Indicative of the deregulation of common pathways by gene orthologs, common gene signatures were observed in cases with c-MAF and MAFB activation and CCND1 and CCND3 activation, the latter consisting of 2 subgroups, one characterized by expression of the early B-cell markers CD20 and PAX5. A low incidence of focal bone disease distinguished one and increased expression of proliferation-associated genes of another novel subgroup. Comprising varying fractions of each of the other 6 subgroups, the proliferation subgroup dominated at relapse, suggesting that this signature is linked to disease progression. Proliferation and MMSET-spike groups were characterized by significant overexpression of genes mapping to chromosome 1q, and both exhibited a poor prognosis relative to the other groups. A subset of cases with a predominating myeloid gene expression signature, excluded from the profiling analyses, had more favorable baseline characteristics and superior prognosis to those lacking this signature.

UR - http://www.scopus.com/inward/record.url?scp=33745779502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745779502&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-11-013458

DO - 10.1182/blood-2005-11-013458

M3 - Article

C2 - 16728703

AN - SCOPUS:33745779502

VL - 108

SP - 2020

EP - 2028

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -